Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269131 | 0.84 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL1270342 | 0.84 | EGLN1 (1.00) | EGLN1BBOX1FTOTHRATHRB | |
| SCHEMBL1270465 | 0.84 | EGLN1 (0.78) | EGLN1BBOX1FTOEGLN2THRA | |
| SCHEMBL1656947 | 0.81 | EGLN1 (0.67) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL1269046 | 0.78 | EGLN1 (1.00) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL1657022 | 0.77 | EGLN1 (0.63) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL2881416 | 0.77 | EGLN1 (0.62) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL965014 | 0.77 | EGLN1 (0.62) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL30274451 | 0.77 | EGLN1 (0.62) | EGLN1BBOX1FTOEGLN2 | |
| SCHEMBL1656054 | 0.76 | EGLN1 (0.62) | EGLN1BBOX1FTOEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | claimed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | claimed |
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | EGLN1 5/4885BBOX1 751/4885FTO 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.